Back to Search Start Over

BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN).

Authors :
Gaisl T
Turnbull CD
Weimann G
Unger S
Finger R
Xing C
Cistulli PA
West S
Chiang AKI
Eckert DJ
Stradling JR
Kohler M
Source :
The European respiratory journal [Eur Respir J] 2021 Nov 18; Vol. 58 (5). Date of Electronic Publication: 2021 Nov 18 (Print Publication: 2021).
Publication Year :
2021

Abstract

Competing Interests: Conflict of interest: This work was supported by Bayer (sponsor). G. Weimann, S. Unger, R. Finger and C. Xing are employees (including stock options) of the sponsor. T. Gaisl, C.D. Turnbull, P.A. Cistulli, S. West, D.J. Eckert, J.R. Stradling and M. Kohler report personal fees from Bayer during the conduct of the study. P.A. Cistulli, A.K.I. Chiang, D.J. Eckert, J.R. Stradling and M. Kohler report grants from Bayer (all through their respective employer) during the conduct of the study. P.A. Cistulli has an appointment to an endowed academic Chair at the University of Sydney that was created from ResMed funding. He receives no personal fees and this relationship is managed by an Oversight Committee of the University. He has received research support from ResMed, SomnoMed, and Zephyr Sleep Technologies, outside the submitted work. He is a consultant to Zephyr Sleep Technologies, Signifier Medical Technologies, SomnoMed, and ResMed and writer for Wolters Kluwer and Quintessence, outside the submitted work. He has a pecuniary interest in SomnoMed related to a previous role in R&D 2004, outside the submitted work. A.K.I. Chiang and D.J. Eckert report grants from Cooperative Research Centre Project Grant (Australian Government, Academia and Industry collaboration, Industry partner: Oventus Medical), outside the submitted work. D.J. Eckert reports research grants and personal fees from Apnimed and is member of the advisory board of Apnimed, outside the submitted work. J.R. Stradling reports personal fees from Resmed UK, outside the submitted work. M. Kohler reports personal fees from Novartis, grants and personal fees from GSK, grants and personal fees from Roche, personal fees from Boehringer Ingelheim, personal fees from Mundipharma, personal fees from OM Pharma, personal fees from AstraZeneca, all outside the submitted work; and he is a founder and board member of Deep Breath Intelligence Ltd, a company that provides services in the field of breath analysis.

Details

Language :
English
ISSN :
1399-3003
Volume :
58
Issue :
5
Database :
MEDLINE
Journal :
The European respiratory journal
Publication Type :
Report
Accession number :
34531274
Full Text :
https://doi.org/10.1183/13993003.01937-2021